Genetic variation in CYP2A6-mediated nicotine metabolism alters smoking behavior

Therapeutic Drug Monitoring

Volumn 24, Issue 1, 2002, Pages 163-171

  Tyndale, Rachel F ^a   Sellers, Edward M ^a  

^a UNIVERSITY OF TORONTO   (Canada)

Author keywords

CYP2A6 Smoking; Genetic variation; Nicotine metabolism

Indexed keywords

CARBON MONOXIDE; COTININE; COUMARIN; CYTOCHROME P450 2A6; HYPERICUM PERFORATUM EXTRACT; METHOXSALEN; NICOTINE; PAROXETINE; SELEGILINE; TRANYLCYPROMINE;

CONFERENCE PAPER; DNA POLYMORPHISM; DRUG BIOAVAILABILITY; ENZYME ACTIVITY; GENE LOCUS; GENETIC VARIABILITY; HUMAN; LUNG CANCER; PRIORITY JOURNAL; SMOKING; TOBACCO DEPENDENCE; URINALYSIS;

ARYL HYDROCARBON HYDROXYLASES; CYTOCHROME P-450 ENZYME SYSTEM; HUMANS; MIXED FUNCTION OXYGENASES; NICOTINE; SMOKING; VARIATION (GENETICS);

EID: 0036146769     PISSN: 01634356     EISSN: None     Source Type: Journal    
DOI: 10.1097/00007691-200202000-00026     Document Type: Conference Paper

References (141)

1. Genetic and environmental contributions to smoking
2. Genetic and social determinants of initiation and age at onset of smoking in Australian twins
3. The genetics of smoking persistence in men and women: A multicultural study
4. The genetics of smoking initiation and quantity smoked in Dutch adolescent and young adult twins
5. Genetic influence on smoking-A study of male twins
6. Abuse liability and pharmacodynamic characteristics of intravenous and inhaled nicotine
7. Nicotine intake its regulation by smokers
8. Smoking behavior and compensation: A review of the literature
9. Drug therapy. Pharmacologic aspects of cigarette smoking and nicotine addition
10. Intravenous nicotine replacement suppresses nicotine intake from cigarette smoking
11. Drinking coffee and carbonated beverages blocks absorption of nicotine from nicotine polacrilex gum
12. Role of human cytochrome P4502A6 in C-oxidation of nicotine
13. A major role for CYP2A6 in nicotine C-oxidation by human liver microsomes
14. Metabolism of nicotine to cotinine studied by a dual stable isotope method
15. The CYP2A3 gene product catalyzes coumarin 7-hydroxylation in human liver microsomes
16. Interindividual variability of coumarin 7-hydroxylation in healthy volunteers
17. Interindividual variability of coumarin 7-hydroxylation in a Turkish population
18. Nicotine metabolism defect reduces smoking
19. Duplications and defects in the CYP2A6 gene: Identification, genotyping, and in vivo effects on smoking
20. Inhibition of cytochrome P450 2A6 increases nicotine's oral bioavailability and decreases smoking
21. Inhibiting CYP2A6 decreases smoking and increases the detoxification of the procarcinogen 4-(methylnitrosamino)-1-(3-pyridyl)-1-butanone (NNK)
22. Variable CYP2A6-mediated nicotine metabolism alters smoking behavior and risk
23. Mimicking gene defects to treat drug dependence
24. A new deleted allele in the human cytochrome P450 2A6 (CYP2A6) gene found in individuals showing poor metabolic capacity to coumarin and (+)-cis-3,5 dimethyl-2-(3-pyridyl)thiazolidin-4-one hydrochloride (SM 12502)
25. Deficient nicotine metabolism in an individual homozygous for CYP2A6*2
26. Science, medicine and the future: Pharmacogenetics
27. Nicotine and cotinine elimination pharmacokinetics in smokers and nonsmokers
28. Importance of nicotine metabolism in understanding the human biology of nicotine
29. Evidence for urinary excretion of glucuronide conjugates of nicotine, cotinine, and trans-3′-hydroxycotinine in smokers
30. The pharmacokinetics of cotinine in plasma and saliva from non-smoking healthy volunteers
31. Kinetics of cotinine after oral and intravneous administration to man
32. Rate of increase of plasma drug level influences subjective response in humans
33. The mammalian metabolism of nicotine: An overview
34. Metabolism of nicotine by rat liver cytochromes P-450. Assessment utilizing monoclonal antibodies to nicotine and cotinine
35. Pharmacokinetics of (S)-nicotine and metabolites in humans
36. Nicotine metabolism by cDNA-expressed human cytochrome P-450s
37. Characterization of CYP2A6 involved in 3′-hydroxylation of cotinine in human liver microsomes
38. Roles of CYP2A6 and CYP2B6 in nicotine C-oxidation by human liver microsomes
39. Clinical pharmacology of oral cotinine
40. Effects of cotinine on information processing in nonsmokers
41. Effects of cotinine on cigarette self-administration
42. The use of biologic fluid samples in assessing tobacco smoke consumption
43. Characterization of multiple products of cytochrome P450 2A6-catalyzed cotinine metabolism
44. Deficient cotinine formation from nicotine is attributed to the whole deletion of the CYP2A6 gene in humans
45. The significance of the homozygous CYP2A6 deletion on nicotine metabolism: A new genotyping method of CYP2A6 using a single PCR-RFLP
46. Relationship between interindividual differences in nicotine metabolism and CYP2A6 genetic polymorphism in humans
47. Interindividual variations in human liver cytochrome P-450 enzymes involved in the oxidation of drugs, carcinogens and toxic chemicals: Studies with liver microsomes of 30 Japanese and 30 Caucasians.ourna
48. Purification and characterization of human liver microsomal cytochrome P-450 2A6
49. Identification of the human liver cytochrome P-450 responsible for coumarin 7-hydroxylase activity
50. Ethnic-related differences in coumarin 7-hydroxylation activities catalyzed by cytochrome P4502A6 in liver microsomes of Japanese and Caucasian populations
51. Metabolism of [3-14C] coumarin by human liver microsomes
52. Inhibition of coumarin 7-hydroxylase activity in human liver microsomes
53. Species differences and interindividual variation in liver microsomal cytochrome P450 2A enzymes: Effects on coumarin, dicumarol, and testosterone oxidation
54. Variability of coumarin 7 and 3-hydroxylation in a Jordanian population is suggestive of a functional polymorphism in cytochrome P450 CYP2A6
55. Pharmacokinetics of coumarin and its 7-hydroxy-metabolites upon intravenous peroral administration of coumarin in man
56. Pilot study on bioavailability of coumarin and 7-hydroxycoumarin upon peroral administration of coumarin in a sustained-release dosage form
57. Deletion of the entire cytochrome P450 CYP2D6 gene as a cause of impaired drug metabolism in poor metabolizers of the debrisoquine/sparteine polymorphism
58. Cytochrome P450 2D6.1 and cytochrome P450 2D6.10 differ in catalytic activity for multiple substrates
59. Comparison of three CYP2D6 probe substrates and genotype in Ghanaians, Chinese and Caucasians
60. A novel single nucleotide polymorphism altering stability and activity of CYP2a6
61. Patterns of cigarette consumption and cotinine levels among African American women smokers
62. Racial and ethnic differences in serum cotinine levels of cigarette smokers:Third national health and nutrition examination survey, 1988-1991
63. Nicotine metabolism and intake in black and white smokers
64. Factors associated with nicotine dependence among African American women cigarette smokers
65. Cotinine levels in Southeast Asian smokers
66. Nicotine metabolism and CYP2A6 allele frequencies in Koreans
67. Organization and evolution of the cytochrome P450 CYP2A-2B-2F sub family gene cluster on human chromosome 19
68. Identification of a new human CYP2A gene fragment with close linkage to CYP2GP1
69. Identification and tissue distribution of the novel human cytochrome P450 2S1 (CYP2S1)
70. The CYP2A gene sub-family: Species differences, regulation, catalytic activities and role in chemical carcinogenesis
71. Human cytochrome P450 CYP2A 13: Predominant expression in the respiratory tract and its high efficiency metabolic activation of a tobacco-specific carcinogen, 4-(methylnitrosamino)-1-(3-pyridyl)-1-butanone
72. CYP2A6 gene deletion reduces susceptibility to lung cancer
73. Characterization and PCR-based detection of a CYP2A6 gene deletion found at a high frequency in a Chinese population
74. Identification and characterization of novel polymorphisms in the CYP2A locus: Implications for nicotine metabolism
75. CYP2A6 genetic polymorphisms and liver microsomal coumarin and nicotine oxidation activities in Japanese and Caucasians
76. A single amino acid substitution (Leul60His) in cytochrome P450 CYP2A6 causes switching from 7-hydroxylation to 3-hydroxylation of coumarin
77. Deficient C-oxidation of nicotine
78. A genetic polymorphism in coumarin 7-hydroxylation: Sequence of the human CYP2A genes and identification of variant CYP2A6 alleles
79. Genotyping of human cytochrome P450 2A6 (CYP2A6), a nicotine C-oxidase
80. Low frequency of CYP2A6 gene polymorphism as revealed by a one-step polymerase chain reaction method
81. Genetic polymorphism of CYP2A6 in the German population
82. Functional variants at CYP2A6: New Genotyping methods, population genetics, and relevance to studies of tobacco dependence
83. Genetic polymorphism of drug metabolizing enzymes: New mutations in CYP2D6 and CYP2A6 genes in Japanese
84. CYP2A6*6, a novel polymorphism in cytochrome p450 2A6, has a single amino acid substitution (R128Q) that inactivates enzymatic activity
85. Identification of a single nucleotide polymorphism in the TATA box of the CYP2A6 gene: Impairment of its promoter activity
86. Genotyping Human CYP2A6 variants
87. Pharmacogenetic risk for drug dependence
88. P450 in opiate addiction: A deficient phenotype? Chapter 10
89. Twin cnocordance for a bnary trait. II. Nested analysis of ever-smoking and ex-smoking traits and unnested analysis of a committed-smoking trait
90. Individual differences in sensitivity to nicotine: Implications for genetic research on nicotine dependence
91. Smoking and alcohol consumption in adult male twins: Genetic heritability and shared environmental influences
92. Common genetic vulnerability for nicotine and alcohol dependence in men
93. Genetic and environmental influences on adolescent substance use and abuse
94. Tobacco consumption in Swedish twins reared apart and reared together
95. Simultaneous gas chromatographic determination of methamphetamine, amphetamine, their p-hydroxylated metabolites in plasma and urine
96. Nicotine blood levels and subjective craving for cigarettes
97. The use of long PCR to confrm three common alleles at the CYP2A6 locus and the relationship between genotype and smoking habit
98. Individual differences in urinary cotinine levels in Japanese smokers:Relation to genetic polymorphism of drug-metabolizing enzymes
99. An improved assay shows no association between the CYP2A6 gene and cigarette smoking behavior
100. CYP2A6 genotype and smoking
101. Genetic polymorphism of cytochrome P450 2A6 in a case-control study on lung cancer in a French population
102. Frequency of CYP2A6 gene deletion and its relation to risk of lung and esophageal cancer in the Chinese population
103. Polymorphisms in genes involved in neurotransmission in relation to smoking
104. Misclassification of smoking in a follow-up population study in southern Germany
105. Nicorette usage and attitude study, Europe 1996
106. Trends in cigarette smoking cessation in the United States
107. Reducing the urge to smoke
108. Nicotine gum: Dose-related effects on cigarette smoking and subjective ratings
109. 2′-hydroxylation of nicotine by cytochrome P450 2A6 and human liver microsomes: Formation of a lung carcinogen precursor
110. Tobacco smoke carcinogens, and lung cancer
111. DNA adduct formation from tobacco-specific N-nitrosamines
112. Nicotine-derived N-nitrosamines and tobacco-related cancer: Current status and future directions
113. Cytochrome P450 2E1 and 2A6 as major catalyzts for metabolic activation of N-nitrosodialklamines and tobacco-related nitrosamines in human liver microsomes
114. A tobacco smokederived nitrosamine, 4-(methylnitrosamino)-1-(3-pyridyl)-1-butanone, is activated by multiple human cytochrome P450s including the polymorphic human cytochrome P4502D6
115. Biochemistry, biology, and carcinogenicity of tobacco specific N-nitrosamines
116. Inhibition of carcinogenesis by isothiocyanates
117. Human cytochrome P450IIA3: CDNA sequence, role of the enzyme in the metabolic activation of promutagens, comparison to nitrosamine activation by human cytochrome P450IIE1
118. Specificity of cytochrome P450 2A3-catalyzed alpha-hydroxylation of N′- nitrosonornicotine enantiomers
119. Evidence for cytochrome P450 2A6 and 3A4 as major catalyzts for N′- nitrosonornicotine alpha-hydroxylation by human liver microsomes
120. Kinetic analysis of the activation of 4-(methylnitrosamino)-1-(3-pyridyl)-1-butanone by heterologously expressed human P450 enzymes and the effect of P450-specific chemical inhibitors on this activation in human liver microsomes
121. Comparative metabolism of the tobacco-related carcinogens benzo[a]pyrene. 4-(methylnitrosamino)-1-(3-pyridyl)-1-butanone, 4-(methylnitrosamino)-1-(3-pyridyl)-1-butanol, and N′- nitrosonornicotine in human hepatic microsomes
122. Enzymes involved in the bio-activation of 4-(methylnitrosamino)-1-(3-pyridyl)-1-butanone in patas monkey lung and liver microsomes
123. Interactions of ingested food, beverage, and tobacco components involving human cytochrome P4501A2, 2A6, 2E1, and 3A4 enzymes
124. High variability of nitrosamine metabolism among individuals: Role of cytochromes P450 2A6 and 2E1 in the dealkylation of N-nitrosodimethylamine and N-nitrosodiethylamine in mice and humans
125. Metabolic activation of N-alkylnitrosamines in genetically engineered Salmonella typhimurium expressing CYP2E1 or CYP2A6 together with human NADPH-cytochrome P450 reductase
126. Development of a Salmonella tester strain sensitive to promutagenic N-nitrosamines: Expression of recombinant CYP2A6 and human NADPH-cytochrome P450 reductase in S. typhimurium YG7108
127. N-nitrosodiethylamine and 4-(methylnitrosamino)-1-(3-pyridyl)-1-butanone induced morphologic transformation of C3H/10T1/2CL8 cells expressing human cytochrome P450 2A6
128. Human cytochrome P450IIA3 CDNA sequence, role of the enzyme in the metabolic activation of promutagens, comparison to nitrosamine activation by human cytochrome P450IIE1
129. The relevance of tobacco-specific nitrosamines to human cancer
130. Stereochemistry of metabolites of a tobacco-specific lung carcinogen in smokers' urine
131. Polygenic inheritance of predisposition to lung cancer
132. Combined genetic polymorphism and risk for development of lung cancer
133. Levelling-off of the risk of lung and bladder cancer in heavy smokers: An analysis based on multicentric case-control studies and a metabolic interpretation
134. Ethnic variations in lung cancer
135. Carcinogenicity of tobacco specific N-nitrosamines (TSNA): The role of the vascular network in the selection of target organs
136. The dose-response relationship between cigarette consumption, biochemical markers and risk of lung cancer
137. Activation of procarcinogens by human cytochrome P450 enzymes
138. DNA-expressed human cytochrome P450s: A new age of molecular toxicology and human risk assessment